8-K: EyePoint Pharmaceuticals Announces Topline Results from Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals' Phase 2 PAVIA trial of DURAVYU for non-proliferative diabetic retinopathy showed stable or improved disease severity and reduced progression rates at nine months, though the primary endpoint was not met.

Summary

• EyePoint Pharmaceuticals announced topline results from its Phase 2 PAVIA clinical trial evaluating DURAVYU for non-proliferative diabetic retinopathy (NPDR).
• The trial did not meet its pre-specified primary endpoint, which was a two-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at nine months.
• However, DURAVYU demonstrated a biologic effect, with 86% of patients in the 3mg arm and 80% in the 2mg arm showing stable or improved disease at nine months, compared to 70% in the control arm.
• The study also showed reduced rates of NPDR progression, with 0% of patients in the 3mg arm and 5% in the 2mg arm worsening by two steps, compared to 10% in the control arm.
• The safety profile of DURAVYU was favorable, with no drug-related serious adverse events reported.
• The company plans to analyze the full 12-month data to determine the future path for DURAVYU as a potential treatment for NPDR.
• The company is also preparing to initiate the LUGANO trial, a pivotal Phase 3 trial for wet AMD, in the second half of 2024.
• Topline data from the Phase 2 VERONA trial in diabetic macular edema (DME) is expected in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the drug showed some positive effects, the primary endpoint was not met, which is a setback. However, the company is progressing with other trials and has a strong cash position.

Positives

• DURAVYU showed a biologic effect in patients with NPDR.
• The treatment demonstrated a favorable safety and tolerability profile.
• There were reduced rates of NPDR progression at nine months.
• The majority of patients treated with DURAVYU experienced stable or improved disease severity.
• The company is progressing with other clinical trials for different retinal diseases.

Negatives

• The Phase 2 PAVIA trial did not meet its pre-specified primary endpoint of a two-step improvement in DRSS at nine months.
• Similar proportions of participants treated with DURAVYU and sham injection achieved a 2-step improvement in DRSS score at nine months.

Risks

• The future of DURAVYU as a treatment for NPDR is uncertain pending analysis of the full 12-month data.
• Regulatory approval for DURAVYU is not guaranteed and the timeline for potential approval is uncertain.
• The company's success depends on the effectiveness and timeliness of clinical trials.
• There are risks associated with the company's dependence on contract research organizations and other outside vendors.
• The company faces risks related to intellectual property protection and potential infringement.

Future Outlook

The company plans to analyze the full 12-month data from the PAVIA trial to determine the future path for DURAVYU in NPDR, and is preparing to initiate Phase 3 trials for wet AMD in the second half of 2024, with topline data from the Phase 2 VERONA trial in DME expected in the first quarter of 2025.

Management Comments

• Jay Duker, M.D., Chief Executive Officer of EyePoint Pharmaceuticals, stated that the objective of the PAVIA trial was to evaluate DURAVYU as a potential treatment in a non-proliferative diabetic patient population.
• Dr. Duker also mentioned that while the trial did not meet the pre-specified primary endpoint, they are encouraged that DURAVYU continues to be well tolerated and appears to reduce rates of NPDR progression at nine months.
• Dr. Duker noted that the company remains focused on preparing for the initiation of the LUGANO trial for wet AMD in the second half of this year.

Industry Context

This announcement is relevant to the broader industry trend of developing sustained-release treatments for retinal diseases, aiming to reduce the frequency of injections required by current therapies. The results of the PAVIA trial will be closely watched by competitors in the space, particularly those developing treatments for NPDR and wet AMD.

Comparison to Industry Standards

• The PAVIA trial results are being compared to existing treatments for NPDR, which often require frequent injections and have limitations in long-term efficacy.
• The company's DURAVYU is being compared to other sustained-release anti-VEGF therapies in development, with a focus on its unique mechanism of action as a pan-VEGF receptor inhibitor.
• The company's wet AMD program is being compared to other companies developing treatments for wet AMD, such as Regeneron's Eylea and Roche's Vabysmo, with a focus on the potential of DURAVYU as a maintenance therapy.
• The company's Durasert technology is being compared to other drug delivery platforms, with a focus on its proven safety and efficacy in FDA-approved products.

Stakeholder Impact

• Shareholders may react negatively to the news that the primary endpoint of the PAVIA trial was not met.
• Patients with NPDR may be hopeful about the potential of DURAVYU, but will need to wait for further data and regulatory approvals.
• Employees may be impacted by the company's strategic decisions regarding the future of DURAVYU.
• The company's suppliers and partners may be affected by the company's clinical trial progress and financial performance.

Next Steps

• The company will analyze the full 12-month data from the PAVIA trial.
• The company plans to provide an update on the path forward for DURAVYU in NPDR.
• The company will initiate the LUGANO trial, a pivotal Phase 3 trial for wet AMD, in the second half of 2024.
• The company anticipates topline data from the Phase 2 VERONA trial in DME in the first quarter of 2025.

Key Dates

Keywords

DURAVYU, vorolanib, non-proliferative diabetic retinopathy, NPDR, diabetic retinopathy, retinal diseases, clinical trial, Phase 2, wet AMD, DME, tyrosine kinase inhibitor, Durasert E, EYP-1901